Compare Pfizer Inc (PFE) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Verisign, Inc. — how do they compare? Pfizer Inc trades at $28.24 (market cap $158.56B), while Verisign, Inc. trades at $304.06 (market cap $26.92B). The key difference: Pfizer Inc is far larger — about 5.9× Verisign, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Verisign, Inc. for 123 Days on average.
| PFE | VRSN | |
|---|---|---|
Market Cap | $158.56B | $26.92B |
Volume | 44,138,282 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $29.02 | $310.00 |
52-Week Low | $23.67 | $211.49 |
Typical Hold Time | 158 Days | 123 Days |
Enterprise Value | $210.06B | $28.23B |
Dividend Yield | 6.18% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
VeriSign (VRSN) trades at $305.53, up 3.84% today, with a bullish technical outlook and strong institutional buying. The company reported solid Q2 2026 results with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations slightly. High profitability is evident with a net income margin near 50%, but valuation multiples like P/E of 32.33 are elevated. Recent news includes an antitrust lawsuit and insider selling by the CEO, while major institutions like BlackRock have increased stakes.
The stock offers growth potential from domain registration increases and AI-driven demand, with a consensus price target of $348 implying 14% upside. Risks include regulatory scrutiny from the antitrust case, high debt levels, and premium valuation. Analyst sentiment is positive with 60% buy ratings, but investors should monitor Q3 2026 earnings on October 22 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
